# Analysis: TMO_2024_Q3.txt

*Model: gpt-4o*

---

**Quarter & Company Context**

- **Company Name:** Thermo Fisher Scientific
- **Ticker:** TMO
- **Fiscal Quarter/Year:** Q3 2024
- **Key Macro or Industry Context:** Management highlighted a gradual improvement in market conditions throughout the year, with modest improvements expected to continue into Q4 and 2025. The company is experiencing a headwind from the runoff of COVID-19-related revenues, particularly in vaccines and therapies.

**Headline Financial Results**

- **Revenue:** $10.6 billion (flat YoY)
- **Adjusted EPS:** $5.28 (raised guidance for full-year adjusted EPS to $21.35 - $22.07)
- **Adjusted Operating Margin:** 22.3%
- **Guidance:** Revenue expected to be $42.4 billion to $43.3 billion for the year; adjusted EPS guidance increased by $0.03 at the midpoint.

**Management Commentary**

- **Strategic Initiatives:** Continued focus on high-impact innovation, trusted partner status, and commercial engine. Recent product launches include the Thermo Scientific ILLiad scanning transmission electron microscope and the Applied Biosystems MagMax Sequential DNA RNA Kit.
- **Risks/Challenges:** Ongoing headwinds from the runoff of COVID-19-related revenues. Muted growth in China and the impact of the Inflation Reduction Act (IRA) on large pharma.

**Q&A Highlights**

- **Main Themes:** Analysts focused on the pace of recovery in pharma and biotech, the performance of the PPD (clinical research) business, and the dynamics within the life sciences solutions segment.
- **Management Responses:** Management expressed confidence in a gradual recovery, with biotech funding improving. They highlighted strong execution and strategic customer wins, particularly in the clinical research and pharma services segments.

**Market/Investor Sentiment Signals**

- **Forward-looking Commentary:** Management is optimistic about 2025, expecting a return to organic growth in Q4 2024. They anticipate a reduced headwind from pandemic-related activities in 2025.
- **Surprises vs. Expectations:** The company slightly exceeded EPS expectations but faced a flat revenue growth, which was in line with internal expectations but slightly below some external models.

**Takeaways**

- Thermo Fisher is experiencing gradual improvement in market conditions, with expectations for organic growth in Q4.
- The company raised its full-year EPS guidance, reflecting strong operational performance and cost management.
- Strategic initiatives and product innovations are driving customer wins and long-term growth prospects.
- Challenges remain from the runoff of COVID-19-related revenues and muted growth in China.
- The company is well-positioned for future growth, supported by strong customer relationships and a robust innovation pipeline.

**Other Notable Information**

- **M&A Activity:** The integration of Olink is progressing smoothly, and the binding site acquisition is performing well.
- **Corporate Social Responsibility:** Emphasis on colleague safety, particularly in response to Hurricane Helene, and ongoing commitment to environmental stewardship.
- **Capital Deployment:** Continued focus on strategic M&A and returning capital to shareholders through share buybacks and dividends.